News 2017

Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials

Date: 28/11/2017

28 November 2017, Maastricht, The Netherlands – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced that it secured a €2.5 million grant from the European Commission’s Horizon 2020 programme. (more…)

Mellon Medical secures € 6 million for market introduction of innovation in surgical suture technology

Date: 03/10/2017

3 October 2017, Nijmegen, The Netherlands – Mellon Medical, a Dutch MedTech developer of a platform technology for suturing with one hand, has raised € 6 million to advance its patented ground breaking global innovation in suturing technology. (more…)

12-month clinical study published on NightBalance’ Sleep Position Trainer

Date: 18/09/2017

18 September 2017 – A clinical study demonstrating the excellent efficacy and compliance of the Sleep Position Trainer, NightBalance’ revolutionary device to treat positional sleep apnea, has been accepted for publication in the professional journal Sleep and Breathing. (more…)

Hemics in the news

Date: 06/09/2017

6 September 2017 – Two articles have appeared in the media related to the initial international commercial success of Hemics. They can be found here (both in the Dutch language): Sprout and Telegraaf.

Hemics goes international and sell first devices in Germany and Belgium

Date: 28/08/2017

28 August 2017, Eindhoven, the Netherlands – The HandScan, a Dutch medical technology innovation, will be used this month for the first time outside the Netherlands. Clinics in Germany and Belgium have purchased the innovative rheumatism scanner from Eindhoven start-up company Hemics. (more…)

ATRO Medical closed a Series A financing round for the development of a polymer based meniscus implant

Date: 17/07/2017

17 July 2017, Nijmegen, The Netherlands – Today ATRO Medical announces the successful closure of a Series A financing round. The funding provided by a syndicate led by Thuja Capital Healthcare (Seed) Fund II and includes Brabant Development Agency, DSM Venturing, Cascara Ventures and Radboud university medical center. (more…)

Nutrileads, NIZO Food Research and Friesland Campina win prestigious EFRO Grant

Date: 08/06/2017

7 June 2017, Wageningen, The Netherlands – NUTRILEADS B.V., a Dutch Nutrition & Health startup, together with NIZO food research (consortium leader) and Friesland Campina, has been awarded a €3,7 million EFRO project called CHALLENGE. (more…)

argenx announces closing of NASDAQ IPO

Date: 23/05/2017

23 May 2017, Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), announced today the closing of its initial public offering in the United States (the “Offering”) of 6,744,750 American Depositary Shares (“ADSs”), at a price to the public of $17.00 per ADS, for gross proceeds of approximately $114.7 million. (more…)

argenx raises approximately $100 million gross proceeds with NASDAQ IPO

Date: 18/05/2017

18 May 2017, Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX, Nasdaq: ARGX) announced today the pricing of its initial public offering in the United States (the “Offering”) with anticipated gross proceeds totalling approximately $100 million from the sale of 5,865,000 American Depository Shares (“ADSs”), at a price to the public of $17.00 per ADS. (more…)

NutriLeads closes series A round to advance the development of its lead nutritional ingredient supporting immune function

Date: 29/03/2017

29 March 2017, Wageningen, The Netherlands -Dutch nutritional health ingredients startup NUTRILEADS B.V. today announces the successful closing of a Series A financing round with existing shareholders DSM VENTURING, PPM OOST, SHIFT INVEST and THUJA CAPITAL. (more…)

Argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases

Date: 21/03/2017

21 March 2017, Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX) today announced that it has entered into a new collaboration with Broteio Pharma B.V. to develop an antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation. (more…)

Cristal Therapeutics successfully closes €12.8 million financing round

Date: 19/01/2017

19 January 2016, Maastricht, The Netherlands – Cristal Therapeutics today announced the closing of a €12.8 million financing round. The financing comes from a consortium headed by Dutch oncology investor Aglaia BioMedical Ventures and Belgian DROIA Oncology Ventures (more…)

Newspaper articles: Hemics install first Handscan device in Dutch hospital

Date: 10/01/2017

10 January 2017, Eindhoven, The Netherlands – The regional Dutch newspaper Eindhovens Dagblad reported on Hemics installing a first Handscan device in a major Dutch hospital.  (more…)